The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadj...

Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most common adverse events. The positive results obtained in early phase 2 clinical trials with gefit...

Patients with newly diagnosed non-small cell lung cancer (NSCLC) need accurate tumor staging in order to direct appropriate therapy and establish prognosis; the tumor is usually staged using the TNM system. The major imaging modalities currently used for staging this disease are thoracic computed tomography (CT) (including the adrenal glands) and whole body fluorodeoxyglucose (FDG)-positron emi...

More than 170 000 new cases and 150 000 deaths have occurred in 2003 in US owing to lung cancer, which is the leading cancer death reason for men in US. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers [1, 2]. Despite the progress in imaging and diagnostic procedures, non-small cell lung cancer (NSCLC) usually presents as advanced (locally or more frequently dissemi...

MEK MEK162 GDC-0973 GSK1120212 MSC1936369B STAT3 OPB51602 AKT MK2206 Stage a Est. % General treatment recommendations 5-year overall survival b clinical stage path. stage IA 14% Surgical resection 50% 73% IB 10% Surgical resection, can consider adjuvant chemotherapy in selected cases (e.g. tumor size > 4cm) 43% 58% IIA 6% Surgical resection followed by adjuvant chemotherapy 36% 46% IIB 5% Surgi...

Background: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC). Chemotherapy resistance main cause chemotherapy failure. Cullin7 (Cul7) highly expressed in LUAD and associated with poor prognosis. Moreover, Cul7 abnormally overexpressed docetaxel-resistant cells. Therefore, further exploration role molecular mechanism docetaxel necessary.

Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing more than 80% of lung cancer diagnoses. Five-year survival remains at 15%, but new strategies for prevention, early detection, and treatment may improve survival rates. This article provides an overview of updates in NSCLC, with an empha...

Immunotherapy as an option of treatment in cancer has experienced an important development with the inclusion of vaccines. In lung cancer this type of treatment has emerged and vaccines can be classified in three groups: antigen-specific vaccines, tumor cell vaccines, and dendritic cell vaccines. Emepepimut (L-BLP25) and MAGE-A3 have been the vaccines most widely studied. Their promising result...

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on the principles of radiation therapy (RT), which include the following: (1) general principles for early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, and normal tissue dose constraints for early-stage, locally...